<qa>  What was the objective overall response rate?This was an investigational study to assess the objective overall response OOR rate complete response CR partial response PR of imatinib mesylate and hydroxyurea hydroxycarbamide combination therapy in patients with recurrent glioblastoma multiforme brain tumors. This study also evaluated the duration of tumor response as per MacDonald criteria, clinical benefit, progression-free survival rate at 6 and 12 months, and the survival rate at 12 and 24 months. 